Biohaven LTD Form 4 insider transactions

Director Kishan Mehta was granted 68,693 stock options in Biohaven Ltd. as part of standard equity compensation.

Director Gregory Bailey was granted 68,693 stock options in Biohaven Ltd. as part of a standard equity compensation arrangement.

Director Michael Thomas Heffernan was granted 68,693 stock options in Biohaven Ltd. as part of standard compensation.

Director Irina Antonijevic was granted 68,693 stock options in Biohaven Ltd. as part of a standard equity compensation arrangement.

Director John W. Childs was granted 68,693 stock options in Biohaven Ltd. as part of a standard equity compensation arrangement.

Director Robert J. Hugin was granted 68,693 stock options in Biohaven Ltd. as part of a standard equity compensation arrangement.

Director Julia P. Gregory was granted 68,693 stock options in Biohaven Ltd. as part of an equity compensation arrangement.

Biohaven Ltd. Director Kishan Mehta reported gifting 17,342 common shares to a family irrevocable trust, maintaining direct ownership of 5,320 shares.

Biohaven Ltd.'s Chief Financial Officer, Matthew Buten, was granted 175,000 stock options with an exercise price of $11.52, vesting over four years.

Biohaven Ltd. granted its SVP of Clinical Operations, Kimberly Gentile, 175,000 stock options with an exercise price of $11.52, vesting over four years.

Biohaven Ltd. has granted its VP, Chief Accounting Officer, George C. Clark, 50,000 stock options with a vesting schedule over four years.

Biohaven Ltd.'s Chief Scientific Officer, Bruce Car, was granted 175,000 stock options with an exercise price of $11.52, vesting over four years.

Biohaven Ltd.'s CEO, Vlad Coric, was granted 550,000 stock options with an exercise price of $11.52, vesting over four years.

Biohaven Ltd.'s SVP of Clinical Operations, Kimberly Gentile, exercised restricted share units and had shares withheld for tax obligations on January 5, 2026.

Biohaven Ltd.'s Chief Financial Officer, Matthew Buten, reported the scheduled vesting of restricted share units and subsequent tax-related share withholding on January 5, 2026.

Biohaven Ltd. CEO Vlad Coric reported the vesting of 14,250 restricted share units and the withholding of 7,430 shares for tax purposes on January 5, 2026.

Biohaven Ltd.'s Chief Scientific Officer, Bruce Car, reported the vesting of restricted share units and subsequent tax-related share withholding.

Biohaven Ltd.'s VP, Chief Accounting Officer, George C. Clark, increased his direct beneficial ownership of common shares following the vesting of restricted share units.

Biohaven Ltd.'s VP, Chief Accounting Officer, George C. Clark, purchased 17,000 common shares at an average price of $8.5159.

Biohaven Ltd. Director Gregory Bailey acquired 400,000 common shares at $7.50 each through an underwritten public offering.

Biohaven Ltd. Director and 10% owner John W. Childs acquired over 3.3 million common shares in an underwritten public offering.

Biohaven Ltd. CEO and Director Vlad Coric acquired 666,666 common shares for approximately $5 million through an underwritten public offering.

Director Irina Antonijevic acquired 31,716 stock options in Biohaven Ltd. on May 5, 2025, according to a Form 4 filing.

Director Michael Thomas Heffernan acquired 31,716 stock options in Biohaven Ltd. on May 5, 2025.

Director Gregory Bailey reports acquisition of 31,716 Biohaven Ltd. stock options on May 5, 2025.

Director Kishan Mehta acquired 31,716 stock options in Biohaven Ltd. on May 5, 2025.

Director Julia P. Gregory acquired 31,716 stock options in Biohaven Ltd. on May 5, 2025.

Director John W. Childs acquired 31,716 stock options in Biohaven Ltd. on May 5, 2025.

A Biohaven director, Robert J. Hugin, acquired 31,716 stock options at an exercise price of $22.62 on May 5, 2025.

Director John W. Childs reports purchasing additional Biohaven Ltd. shares through various trusts.